Member Info for HedgeHogarth

Some laughable comments

You cannot blame KM for the share price. Its moving down on very low volumes - nothing to worry about

Very low risk - KDNC has a number of assets. Even if you don't want to but the broker's 40p+ fair value. For me, there is plenty of value here to comfortably support a SP of 20-25p.

Wish i had some spare funds to get some more at this price - but my funds are all tied up in another stock

He liked my tweet yesterday ??

one2one - maybe just ask your teacher at school on Monday

Yes - clinical trials cost Lots and Lots and Lost of money. Phase 1 / 2 are cheaper, but phase 3 is very expensive.

But - if you do a small amount of research you will see that IF phase 1 is positive it starts to de-risk the process of getting a drug to market. This, on average, as up to 10x multiple on SP.

Hemo are unlikely to fund phase 3 trials on their own, This is where partners come in. The rewards of getting a drug to market are huge, so plenty in it for Hemo and a Partner.

Condom - its all about buy low, sell high.
If indeed Whyme did buy shares here which i very much doubt, he bought too high if he was looking to exit now
If he or she is patient however, I am very confident they will be able to sell high in the future

Don't spoil my afternoon - I'm still hoping it lands today!!! ;-)

Noooooo
Please don't set the expectation that an RNS will land on Monday. It's pure speculation

Thanks H4H - Good to hear.

I will afford the trolls a small thank you for their role in dragging the SP down with either their trading or manipulation - Brought my average down nicely :-)

I'm always banging on about how slow Biotech is as a sector - That is why we are at such a special point now with HEMO

Whether it is days or weeks, we make that move into the Clinic.
We will get a thorough update on all aspects of the business in the Annual Results - If some on this board are correct, this could include a number of really exciting updates that we have not been told about
AND - I really hope we get some good Comms from the company - an Investor call and hopefully an interview or two

Mr India - I am not sure what planet you are on but it is not the same as the one I am on
We agree that the next News update is key here
Where we disagree is the relevance of the current price action - the movements just reflect a relatively small amount of shares being transacted. A combination of trading, MM tactics etc - it really is no reflection on the genuine value of the company

The SP could rocket on the right news - This is based on 2 reasons , (1) The opportunity to trade what would become very clear is a highly undervalued SP and (2) a new breed of investor who looks at clinical Biotechs, PIs, Funds (where their investment criteria exists) and hopefully Big Pharma that see the potential

You comparison to other sticks is strange - the 50 -100 stocks that i keep tabs on does not seem to behave any differently to Hemo

Its not about the US market opening - It's about the US investors waking up!
Did you know that it's possible to invest in UK listed stocks when living in the US?

Traders Day today

Would make my day if we get an RNS when US market opens

Everyone is asking for news. We have ALREADY had lots in 2023 and its only the end week of March. Lots more news than majority of listed companies.

Its only about 30 days or so until we will get a thorough update on EVERYTHING as part of the annual report. And it highly likely we WILL get an update before that on something.

For those that think HEMO may have pitched for a Biodefence grant - those get publicly announced very shortly. As i have said before, looking at last year's awards, no reason why Hemo wont be successful given what we heard about CBR it the last update

Gotta love weeks like this
Sorts out the MEN from the BOYS
We are seeing the WEAK hands

As Taylor Swift (almost said)

The traders gonna trade, trade, trade trade, trade
I shake it off, i shake it off

If anyone thinks that a few bets against the SP, a few MM games or a few weak hands panicking and selling makes ANY difference to the performance of Hemogenyx, you deserve to lose money or miss the opportunity to make money

Mr India, JHFH has vouched for you and hence why I make every effort to be respectful.

However, it's like have a 5 year old on this forum. You claim to have invested significantly, you claim to have researched yet you come here every day and whinge. You need to take a long hard look at yourself mate, I mean that ok all seriousness.

Two reasons Mr India, they have already taken their positions. 2.3p was an excellent entry point. As is 2.1p today, but most are not lucky enough to catch the bottom and it won't make that much difference in the medium / long term.

Also, you are making the assumption that those who bought at those prices have more funds to invest, even if they wanted to.

I am NOT a trader either. The thought scares me. The market is very devious and clever at making it hard to know what the short term direction is of a share price.

I am a LTHer, prepared to hold for as long as it takes to meet my investment objectives.

Hemo HAVE been working towards this moment for many, many years, Its roots go back to Vlad's days at Cornwell. So LTHers are so excited that HEMO are within a whiskers of some real pivotal moments:

1 - Within sight of starting clinical trials - this is a key transitional stage for Biotechs and with it, normally the value of the company will reflect this. If Phase 1 data is good, this can propel the mCap significantly (Vlad recently tweeted x10)

2. Great CBR update early in the year. In Vivo results using live viruses in a Gov restricted lab are eagerly anticipated. Further proof of concept would be pivotal and likely to attract greater interest from Big Pharma.

3. Biodefense awards will be announce in March. Vlad has been very interested in Biodefense. It's highly probable that HEMO have applied for a significant grant. Biodefense offers another great route to market for CBR and could support its ongoing development and maybe even help i get fast tracked.

4. Potential Corporate news - Potential to attract lots of new investment through a dual listing on Nasdaq / Partnership updates / Updated website / Investor presentation is due

It was nice to see HEMO secure the recent funding of £4m (secured at almost double the SP of the previous raise) . That helped bolster it's finances in what could be a brilliant year for the company.

I am excited as a LTH - which is why waiting for news sometime feels like waiting for Christmas. It's helped me a lot with perspective and learning the value of patience.

one2one - you are sadly mislead my friend
Blue indicates the traded price was closer to the ASK at the time it gets reported
Red indicates the traded was close to the BID at the time it gets reported
Black indicated the traded was half way between the two at the time it gets reported

That is all - it is purely a formula, the colours do not reflect the real amount of buys and sells. Infact, i can assure you that it is VERY misleading

Mr India - your post is very misleading

The SP went from 1.1p to 14p in FY20- that is a phenomenal performance
I myself did very well in 2020

LTHs will have paid 2-3p for their shares - they had almost 1 year to take significant profits between 2020 and 2021

**** can happen - we were all very confident that their could be a deal on CDX - it did not happen. We have to accept that.

Investors in companies this size have to be aware of the regular need to raise - most Biotechs do not generate revenue. Success for Biotechs is usually being bought up or partnered by a deep pocketed Pharma who fund the trials through upfront payments.

Savvy, experienced investors will have de-risked an any point when the SP was between 100% and 1000% up (depending on their entry point). The Mint episode did not turn out well, but the company was always going to need significant funding when the opportunity to address cashflow through a CDX upfront payment did not materialise.

All investors need to have a clear exit plan - even loyal long term holders. Biotech, like mining and many other sectors can be a bumpy, volatile ride. As JHFH as previously posted, HEMO is at a great point for investments as the next 12-18mths is relatively low risk. Risk gets higher in latter trials OR much sooner in the development journey which Hemo have now passed. Hemo are not a one trick pony, and have multiple routed to the clinic.

The reality is this share will probably have about 200 flattish days, 50 red days and a small number of very very blue days.

Various news items that are very likely have the potential to gives us those very very blue days. That's why we hold

It's not that difficult, buy low, sell high.